CaroGen Funding: How Much Did They Raise & Key Investors

How Much Did CaroGen Raise?
Funding & Key Investors

CaroGen Corporation has solidified its position in the biotechnology sector by securing a total of $2.2M in capital to accelerate its proprietary immunotherapy pipeline. The most recent strategic investment of $2.1M marks a significant milestone in the company's trajectory, providing the necessary resources to transition its innovative RNA-based AVIDIO platform from pre-clinical development toward human clinical trials. This infusion of financing underscores investor confidence in the firm's ability to address high-unmet-need indications through advanced molecular engineering.

The company's growth narrative is defined by a disciplined approach to research and development, supported by both public sector grants and private equity backing. By leveraging its unique AVIDIO technology, CaroGen is positioning itself as a formidable player in the immuno-oncology and infectious disease landscape, aiming to deliver transformative therapeutic outcomes for patients suffering from chronic hepatitis B and ovarian cancer.

What is CaroGen?

CaroGen

Business Services

Research & Development

CaroGen Corporation is a clinical-stage biotechnology firm specializing in the development of next-generation immunotherapy and vaccine solutions. At the core of its operations is the AVIDIO platform, an RNA-based technology designed to elicit robust immune responses against complex disease targets. The company is currently focused on advancing two primary candidates: CARG-201, targeting chronic hepatitis B, and CARG-2020, a therapeutic candidate for ovarian cancer. With a robust intellectual property portfolio and support from institutions such as the NIH and DoD, CaroGen operates at the intersection of oncology and virology, aiming to redefine standard-of-care protocols through precision medicine.

How much funding has CaroGen raised?

CaroGen has raised a total of $2.2M across 2 funding rounds:

2013

Angel/Seed

$150K

2016

Private Equity

$2.1M

Angel/Seed (2013): $150K with participation from Connecticut Innovations

Private Equity (2016): $2.1M, investors not publicly disclosed

Key Investors in CaroGen

Connecticut Innovations

Connecticut Innovations is the state's strategic venture capital arm and quasi-public agency, providing equity and debt financing to help innovative bioscience and technology companies scale.

Undisclosed Investor

An institutional participant providing private equity backing to support the company's late-stage development initiatives.

Undisclosed Investor

A strategic partner or investment entity contributing to the recent capital round to facilitate the advancement of the AVIDIO platform.

What's next for CaroGen?

With the recent capital injection, CaroGen is poised to accelerate its late-stage pre-clinical studies and prepare for critical regulatory filings. The strategic roadmap involves scaling manufacturing capabilities for its RNA-based candidates and expanding its clinical research team to support upcoming human trials. As the company moves deeper into the clinical development phase, the focus will shift toward establishing strategic partnerships with larger pharmaceutical entities to facilitate global distribution and commercialization. The firm's ability to maintain its momentum will be contingent upon the successful translation of its pre-clinical data into positive clinical outcomes, further validating the AVIDIO platform's potential to disrupt the current immunotherapy market.

See full CaroGen company page

See More Financial Insights